SAB BIO CEO to Participate in Fireside Chat at 2024 Cantor Global Healthcare Conference
September 13, 2024 07:00 ET
|
SAB Biotherapeutics, Inc.
MIAMI, Sept. 13, 2024 (GLOBE NEWSWIRE) -- SAB BIO (Nasdaq: SABS) (the “Company” or “SAB”), a clinical-stage biopharmaceutical company with a novel immunotherapy platform developing a human...
SAB BIO Provides SAB-142 Clinical Trial Progress Update at the European Association for the Study of Diabetes Annual Meeting
September 09, 2024 07:00 ET
|
SAB Biotherapeutics, Inc.
SAB BIO presents clinical trial progress update at EASD conference
SAB BIO to Present at the European Association for the Study of Diabetes 60th Annual Meeting
September 04, 2024 07:05 ET
|
SAB Biotherapeutics, Inc.
MIAMI, Sept. 04, 2024 (GLOBE NEWSWIRE) -- SAB BIO (Nasdaq: SABS) (the “Company” or “SAB”), a clinical-stage biopharmaceutical company with a novel immunotherapy platform developing a human...
SAB BIO Announces Second Quarter 2024 Financial Results and Provides Company Updates
August 08, 2024 17:51 ET
|
SAB Biotherapeutics, Inc.
FDA provided clearance to SAB’s IND Appointed Lucy To as Chief Financial Officer Announced founding of a new Clinical Advisory Board MIAMI, Aug. 08, 2024 (GLOBE NEWSWIRE) -- SAB BIO...
SAB BIO Announces Founding of Clinical Advisory Board to Guide the Development of SAB-142 for Type 1 Diabetes
August 05, 2024 07:30 ET
|
SAB Biotherapeutics, Inc.
MIAMI, Aug. 05, 2024 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq: SABS) (the “Company” or “SAB”), a clinical-stage biopharmaceutical company with a novel immunotherapy platform developing...
SAB BIO Appoints Lucy To as Chief Financial Officer
July 31, 2024 07:30 ET
|
SAB Biotherapeutics, Inc.
SAB BIO Appoints Lucy To as Chief Financial Officer
SAb Biotherapeutics Rebrands as SAB BIO
June 20, 2024 07:20 ET
|
SAB Biotherapeutics, Inc.
New name, logo and website updates, stock symbol will remain SABS With new brand identity, SAB BIO continues drive towards serious unmet needs in type 1 diabetes MIAMI, June 20, 2024 (GLOBE...
SAB Biotherapeutics to Present at the American Diabetes Association 84th Scientific Sessions
June 18, 2024 13:10 ET
|
SAB Biotherapeutics, Inc.
MIAMI, June 18, 2024 (GLOBE NEWSWIRE) -- SAB Biotherapeutics (Nasdaq: SABS) (the “Company” or “SAB”), a clinical-stage biopharmaceutical company with a novel immunotherapy platform developing a...
SAB Biotherapeutics Announces Departure of Chief Financial Officer
May 30, 2024 16:45 ET
|
SAB Biotherapeutics, Inc.
MIAMI, May 30, 2024 (GLOBE NEWSWIRE) -- SAB Biotherapeutics (Nasdaq: SABS) (the “Company” or “SAB”), a clinical-stage biopharmaceutical company with a novel immunotherapy platform developing a human...
FDA Provides Clearance to IND Application for Type 1 Diabetes Therapy SAB-142 by SAB Biotherapeutics
May 21, 2024 07:15 ET
|
SAB Biotherapeutics, Inc.
FDA Provides Clearance to IND Application for Type 1 Diabetes Therapy SAB-142 by SAB Biotherapeutics